Anti-inflammatory drops did not make a significant difference in pain, redness, cells in the anterior chamber or peak IOP in patients who underwent selective laser trabeculoplasty, according to a study. Researchers included 132 patients with primary op…
Author: Healio ophthalmology
VIDEO: Speaker reviews barriers and advancements in glaucoma medical management
At Kiawah Eye, Thomas W. Samuelson, MD, reviews reasons why fewer advancements have been made in pharmacological treatment of glaucoma compared with significant advancements in surgical and laser offerings. For one, existing prostaglandins are already …
EyeGate reports increased net loss in second quarter
EyeGate Pharmaceuticals reported a $3.823 million net loss for the second quarter of 2016, compared with a $1.541 million net loss in the second quarter of 2015.The increased loss was primarily due to expenses related to clinical trials of EGP-437 for …
Some challenges remain in the management of DME
There can be no doubt that anti-VEGF agents have revolutionized the management of diabetic macular edema. Whether we use monoclonal antibodies as in bevacizumab, antibody fragments as in ranibizumab or fusion proteins as in aflibercept to block VEGF, t…
Study: Variable, less than optimal levels of UVA protection offered by side windows of cars
Low levels of ultraviolet A protection provided by side windows in a high number of cars might expose drivers to the negative effects of cumulative UVA light exposure, increasing the risk of cataract and skin cancer.“We tested 29 automobiles from 15 manufacturers. While the front windshields provide a high and consistent level of UVA protection, most side windows are poorly equipped to do so,” Brian S. Boxer Wachler, MD, said in an interview with Ocular Surgery News.
Xiidra for dry eye now available in US
Shire announced that Xiidra, its twice-daily prescription eye drop that is FDA-approved for the treatment of dry eye disease, is now available by prescription in the U.S., according to a press release from the company.The FDA approved Xiidra (lifitegra…
Low-energy femtosecond laser improves visual acuity with minimal trauma
A low-energy femtosecond laser compared well with other laser platforms in terms of visual outcomes and safety in cataract surgery, a German study found.The authors detailed results obtained with the Femto LDV Z8 femtosecond laser (Ziemer Ophthalmic Sy…
Majority of clinicians overestimate harms, benefits of treatment
Most resident and attending internal medicine physicians overestimated both the benefits and harms of common medical tests and treatments, according to findings published in JAMA Internal Medicine.These included the prevention of myocardial infarction …
FDA announces medical device user fee agreement
The FDA and the Advanced Medical Technology Association, the Medical Device Manufacturers Association and the Medical Imaging & Technology Alliance tentatively agreed to a fourth reauthorization of a medical device user fee program. According to an FDA press release, the agreement will enable the FDA to collect $999.5 million in user fees, plus adjustments for inflation, over 5 years, starting in October 2017.
VIDEO: MRI measures water motion in tissue
At Kiawah Eye, George Magrath, MD, of Wills Eye Hospital, Philadelphia, describes how to differentiate types of lacrimal gland lesions using magnetic resonance imaging to measure water motion in tissue.
VIDEO: Prevention measures, patient education mitigate postop dry eye and dissatisfaction
At Hawaiian Eye, Alice T. Epitropoulos, MD, FACS, advises cataract surgeons to take time preoperatively to address ocular surface issues and to educate their patients in order to prevent postoperative dry eye and patient dissatisfaction.
VIDEO: Combined approach with multiple MIGS devices, procedures enhances outcomes
At Hawaiian Eye, Malik Kahook, MD, describes the concept of combined MIGS, or C-MIGS, which incorporates more than one minimally invasive glaucoma surgery device or procedure to target inflow and outflow in the glaucomatous patient. C-MIGS has shown pr…
Oral bisphosphonates associated with increased risk of wet AMD
People who use oral bisphosphonates may have an increased risk of developing wet age-related macular degeneration, according to a study.The risk of AMD increased with duration of oral bisphosphonate use.
Gobiquity receives $6 million in funding for pediatric vision screening program
Gobiquity Mobile Health received $6 million in Series B financing from venture capital firm InterWest Partners to support the company’s pediatric vision screening program.The company announced in a press release that more than 100,000 children have been screened with GoCheck Kids, its flagship product. More than 3,000 children are being screened weekly, signifying more than 300% annual growth.
Imprimis reports $4.6 million net loss in second quarter
Imprimis Pharmaceuticals reported a net loss of $4.6 million, or $0.35 per common share, in the second quarter compared with a net loss of $3.7 million, or $0.39 per common share, in the second quarter of 2015, according to a press release.Total revenu…
VIDEO: Astigmatism management strategies vary in difficult cases
At Hawaiian Eye, Raj K. Rajpal, MD, addresses the variabilities in astigmatism management strategies, especially in more difficult cases with corneal comorbidities.
Intravitreal, topical medications yield similar post-cataract outcomes
Cataract surgery with either topical or intravitreal antibiotics, steroids and NSAIDs yielded similar outcomes, although patients preferred the injection, according to a study.The prospective, randomized study included 25 patients who underwent bilater…
NovaBay reports $2.7 million in net sales in second quarter
NovaBay Pharmaceuticals reported net sales of $2.7 million in the second quarter, a 164% increase from $1 million in the same period of 2015, according to a press release.Net loss was $2.7 million, or $0.36 per share, down from a net loss of $4.9 milli…
High drug prices result of government protection in US
The high cost of prescription drugs in the United States is the result of drug manufacturers being granted government-protected monopolies, according to data published in JAMA Internal Medicine.“The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers and policy makers,” Aaron S. Kesselheim, MD, JD, MPH, of the department of medicine at Brigham and Women’s Hospital and Harvard Medical School, and colleagues wrote. “In addition to their contribution to health care spending, increasing drug costs have important clinical implications. (Read more...)
Inotek completes recruitment for phase 3 trial of trabodenoson
Inotek Pharmaceuticals completed active recruitment for MATrX-1, the first pivotal phase 3 trial of trabodenoson for the treatment of glaucoma.Topline data are expected to be released in December, according to a press release.